Sodium dichloroacetate has been studied for over 50 years. This library covers the mechanism, clinical evidence, safety profile, and sourcing standards.
Peripheral neuropathy, dosing cycles, B1 supplementation, and the honest safety picture.
Read →What to ask before buying DCA — and what the answers reveal about supplier quality.
Read →The Oxford EPiC trial, 79% pain reduction, and the current state of DCA endometriosis research.
Read →The emerging connection between mitochondrial dysfunction, lactate accumulation, and chronic fatigue.
Read →Why MCA is the most important DCA safety test — and why most sellers skip it entirely.
Read →Published dosing ranges, cycle protocols, and what the clinical literature actually shows.
Read →The real differences between the two salt forms and when each might be preferred.
Read →A clear-eyed review of the evidence from cell studies, animal models, and human trials.
Read →What to look for, what to ignore, and what should raise red flags when reviewing a DCA COA.
Read →A complete guide to DCA's chemistry, mechanism of action, and 50-year research history.
Read →What KDCA offers for sodium-restricted protocols and the latest research.
Read →Mitochondrial dysfunction, autonomic considerations, and the sodium-free advantage.
Read →Side effects, MCA risk, cycle protocols, and protective adjuncts.
Read →The PDK/PDH axis and how KDCA restores cellular energy metabolism.
Read →The original clinical application of DCA — decades of evidence reviewed.
Read →The rarest DCA form — what to look for and the quality standards that matter.
Read →Molar equivalence calculations, published ranges, and cycle protocols for KDCA.
Read →Identical mechanism to sodium DCA — what the preclinical and clinical science shows.
Read →Same active anion, different counterion — and why that matters for some researchers.
Read →A complete guide to KDCA — chemistry, mechanism, and how it differs from sodium DCA.
Read →The synergistic case for combining DCA and 2-DG — dual metabolic pathway blockade.
Read →Glucose competition, hypoglycaemia risk, and the metabolic double-edged sword.
Read →Phase I trial ranges, longevity doses, and combination protocol considerations.
Read →Epilepsy, neurodegeneration, AMPK, and how 2-DG protects neurons.
Read →Glycoprotein interference, antiviral mechanisms, and what the research shows.
Read →Why 2-DG is so hard to find at genuine research grade — and what to look for.
Read →Caloric restriction mimesis, AMPK activation, and lifespan extension studies.
Read →From 1950s antiviral research to modern oncology phase I trials.
Read →Complementary mechanisms targeting the Warburg effect from opposite ends of the pathway.
Read →A complete guide to 2-DG — the glucose analogue that blocks glycolysis from the top.
Read →